NASDAQ · FTXH
First Trust Nasdaq Pharmaceuticals ETF
$44.24+$0.47 (+1.07%)
First Trust Nasdaq Pharmaceuticals ETF’s quoted price sits in the upper half of its reported 52-week range, 1.21% below the high.
Loading market information…
AMEX · HECA · USD
Stock price, dividends
Quote as of Oct 30, 2026, 07:59 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Hedgeye Capital Allocation ETF’s quoted price sits in the lower half of its reported 52-week range, 14.01% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
THE COMPANY BEHIND THE TICKER
The Hedgeye Capital Allocation ETF (HECA) employs a dynamic, multi-asset investment strategy. Its primary objective is to maximize capital appreciation over rolling 12-month periods while strictly limiting potential drawdowns to a maximum of 15%. The fund diversifies its holdings across various asset classes, including equities, fixed income instruments, commodities, and currencies. At the heart of HECA's approach is its proprietary "Quad" model. This regime-based, quantitative framework systematically analyzes the directional shifts in key macroeconomic indicators: economic growth, inflation, and monetary policy trends. Portfolio construction and asset allocation are directly informed by these macro signals, strategically aligning investments with prevailing market environments. To further refine its strategy, the fund supplements this framework with both internal analysis and external research to pinpoint nascent themes and emergent investment opportunities. While primarily gaining exposure through US-listed Exchange Traded Funds (ETFs), HECA also retains the flexibility to invest in individual equity and debt securities. An options overlay is an integral component of the strategy, utilized for hedging against downside risk, fine-tuning exposure levels, or enhancing potential returns. Importantly, the portfolio maintains full flexibility, without predetermined geographical allocation limits.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 31, 2026, 06:30 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
KEEP COMPARING
$44.24+$0.47 (+1.07%)
First Trust Nasdaq Pharmaceuticals ETF’s quoted price sits in the upper half of its reported 52-week range, 1.21% below the high.
$24.92-$0.45 (-1.77%)
TappAlpha SPY Growth & Daily Income ETF’s quoted price sits in the upper half of its reported 52-week range, 6.56% below the high.
$77.25-$2.99 (-3.73%)
Putnam Emerging Markets Ex-China ETF’s quoted price sits in the lower half of its reported 52-week range, 18.85% below the high.
$32.24-$0.56 (-1.71%)
AllianzIM U.S. Equity 6 Month Buffer10 May/Nov ETF’s quoted price sits in the upper half of its reported 52-week range, 1.92% below the high.
$36.85-$0.51 (-1.38%)
TrueShares Structured Outcome (March) ETF’s quoted price sits in the upper half of its reported 52-week range, 2.69% below the high.
$40.00-$0.59 (-1.45%)
TrueShares Structured Outcome (April) ETF’s quoted price sits in the upper half of its reported 52-week range, 3.14% below the high.
$37.44$0.00 (0.0%)
Rayliant SMDAM Japan Equity ETF’s quoted price sits in the upper half of its reported 52-week range, 10.67% below the high.
$21.53+$0.34 (+1.61%)
ProShares Ultra Utilities’s quoted price sits in the lower half of its reported 52-week range, 19.66% below the high.
